Cargando…

Correlation of circulating tumor DNA EGFR mutation levels with clinical outcomes in patients with advanced lung adenocarcinoma

BACKGROUND: Circulating tumor DNA (ctDNA) is a promising biomarker for non-invasive epidermal growth factor receptor mutations (EGFRm) detection in lung cancer patients, but existing methods have limitations in sensitivity and availability. In this study, we used the ΔCt value (mutant cycle threshol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiang-Liang, Bai, Ri-Lan, Chen, Xiao, Zhao, Yu-Guang, Wang, Xu, Ma, Ke-Wei, Tian, Hui-Min, Han, Fu-Jun, Liu, Zi-Ling, Yang, Lei, Li, Wei, Gai, Fei, Cui, Jiu-Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654465/ https://www.ncbi.nlm.nih.gov/pubmed/34669636 http://dx.doi.org/10.1097/CM9.0000000000001760

Ejemplares similares

Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma
por: Jiang, Wenting, et al.
Publicado: (2018)

EGFR mutation is positively correlated with C-Met protein expression: a study of 446 resected lung adenocarcinoma
por: Lei, Huizi, et al.
Publicado: (2021)

Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer
por: Li, Wen-Qian, et al.
Publicado: (2020)

A brand new era of cancer immunotherapy: breakthroughs and challenges
por: Bai, Ri-Lan, et al.
Publicado: (2021)

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
por: Shi, Liang, et al.
Publicado: (2021)

Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma
por: Zhou, Xiuzhi, et al.
Publicado: (2018)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs
por: Zhu, Yan-juan, et al.
Publicado: (2017)

Circulating EGFR Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study
por: Li, Shih-Hong, et al.
Publicado: (2022)

EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAF(V600E) mutation: a case report and review of literature
por: Zeng, Ran, et al.
Publicado: (2021)

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
por: Zhang, Qiuyi, et al.
Publicado: (2016)

A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?
por: Han, Guang, et al.
Publicado: (2016)

Correlation between EGFR mutation status and F(18)‐fluorodeoxyglucose positron emission tomography‐computed tomography image features in lung adenocarcinoma
por: Zhu, Lei, et al.
Publicado: (2019)

Differences in Immunological Landscape between EGFR-Mutated and Wild-Type Lung Adenocarcinoma
por: Luo, Jia-Wei, et al.
Publicado: (2021)

EGFR gene-mutation status correlated with therapeutic decision making in lung adenocarcinoma
por: Ren, Yaoyao, et al.
Publicado: (2015)

Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
por: Nicoś, Marcin, et al.
Publicado: (2019)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
por: Cheng, Wen-Chien, et al.
Publicado: (2021)

Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients
por: Sun, Yan, et al.
Publicado: (2014)

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6
por: Wu, Yi-Long, et al.
Publicado: (2017)

The Correlation between EGFR Mutation Status and DNA Content of Lung Adenocarcinoma Cells in Pleural Effusion
por: Du, Yun, et al.
Publicado: (2020)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
por: Wang, Yu, et al.
Publicado: (2021)

EGFR DNA Methylation Correlates With EGFR Expression, Immune Cell Infiltration, and Overall Survival in Lung Adenocarcinoma
por: Xu, Zhanyu, et al.
Publicado: (2021)

Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma
por: Nie, Yunqiang, et al.
Publicado: (2017)

The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer
por: Huang, Wei-Lun, et al.
Publicado: (2015)

Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma
por: Wang, Yuli, et al.
Publicado: (2018)

Unique circulating microRNAs in relation to EGFR mutation status in Japanese smoker male with lung adenocarcinoma
por: Ito, Sachio, et al.
Publicado: (2017)

Correlation between high-resolution computed tomography lung nodule characteristics and EGFR mutation in lung adenocarcinomas
por: Nie, Yunqiang, et al.
Publicado: (2019)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR unusual mutation status in lung adenocarcinomas
por: Alarcão, Ana, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Micropapillary: A component more likely to harbour heterogeneous EGFR mutations in lung adenocarcinomas
por: Cai, Yi-Ran, et al.
Publicado: (2016)

EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
por: Tseng, Chien-Hua, et al.
Publicado: (2017)

Effect of icotinib on advanced lung adenocarcinoma patients with sensitive EGFR mutation detected in ctDNA by ddPCR
por: Chen, Hua-Fei, et al.
Publicado: (2019)

The Relationship between TTF-1 Expression and EGFR Mutations in Lung Adenocarcinomas
por: Shanzhi, Wan, et al.
Publicado: (2014)

Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma
por: Isaka, Tetsuya, et al.
Publicado: (2015)

Radiomics Signature as a Predictive Factor for EGFR Mutations in Advanced Lung Adenocarcinoma
por: Hong, Duo, et al.
Publicado: (2020)

Impact of Radiotherapy Pattern on the Prognosis of Stage IV Lung Adenocarcinomas Harboring EGFR Mutations
por: Zhang, Yingyun, et al.
Publicado: (2021)

Combination therapy of first and third generation EGFR-TKIs for an advanced lung adenocarcinoma patient harboring EGFR mutations and amplification: a case report
por: Chen, Yongxing, et al.
Publicado: (2020)

DOK2 Inhibits EGFR-Mutated Lung Adenocarcinoma
por: Berger, Alice H., et al.
Publicado: (2013)

The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas
por: Cho, Jaeyoung, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2i0jh2dakq1btrsihri8i7porn